Selecting GLP-1 agonists in the management of type 2 diabetes: differential pharmacology and therapeutic benefits of liraglutide and exenatide by Pinkney, Jonathan et al.
© 2010 Pinkney et al, publisher and licensee Dove Medical Press Ltd. This is an Open Access article  
which permits unrestricted noncommercial use, provided the original work is properly cited.
Therapeutics and Clinical Risk Management 2010:6 401–411
Therapeutics and Clinical Risk Management Dovepress
submit your manuscript | www.dovepress.com
Dovepress 
401
Review
open access to scientific and medical research
Open Access Full Text Article
DOI: 10.2147/TCRM.S7313
Selecting GLP-1 agonists in the management of 
type 2 diabetes: differential pharmacology and 
therapeutic benefits of liraglutide and exenatide
Jonathan Pinkney1
Thomas Fox1
Lakshminarayan Ranganath2
1Department of Diabetes and 
endocrinology, Peninsula College of 
Medicine and Dentistry, Plymouth, 
United Kingdom; 2Department of 
Clinical Biochemistry and Metabolic 
Medicine, Royal Liverpool University 
Hospital, Liverpool, United Kingdom
Correspondence: Jonathan Pinkney
Department of Diabetes and 
endocrinology, Peninsula College of 
Medicine and Dentistry, University 
Medicine, Level 7 Derriford Hospital, 
Plymouth Hospitals NHS Trust, 
Crownhill, Plymouth PL8 6DH,  
United Kingdom
Tel +44-1752793498
email jonathan.pinkney@pms.ac.uk
Abstract: Failure of secretion of the incretin hormone glucagon-like peptide-1 (GLP-1) plays 
a prominent role in type 2 diabetes, and restoration of GLP-1 action is an important therapeutic 
objective. Although the short duration of action of GLP-1 renders it unsuited to therapeutic 
use, 2 long-acting GLP-1 receptor agonists, exenatide and liraglutide, represent a significant 
advance in treatment. In controlled trials, both produce short-term glucose-lowering effects, 
with the reduction in hemoglobin A1c of up to 1.3%. These responses are often superior to those 
observed with additional oral agents. However, unlike sulfonylureas, thiazolidinediones, or 
insulin, all of which lead to significant weight gain, GLP-1 receptor agonists uniquely result in 
long-term weight loss of around 5 kg, and higher doses may enhance this further. Reduction in 
blood pressure of 2–7 mm Hg also has been observed. Both drugs produce transient mild gas-
trointestinal side effects; although mild hypoglycemia can occur, this is usually in combination 
with other hypoglycemic therapies. However, serious hypoglycemia and acute pancreatitis are 
rare. The once-daily dosage of liraglutide makes it more convenient than twice-daily dosage of 
prandial exenatide, and a superior glucose-lowering effect was observed in the only head-to-
head comparison reported so far. Besides cost, these considerations currently favor liraglutide 
over exenatide. Further studies are needed to confirm long-term safety, and most importantly, 
that short-term benefits translate into long-term reductions of diabetes-related cardiovascular 
events and other complications.
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Overview of GLP-1
The hormones secreted from the gut endocrine cells play key roles in the control of 
energy balance by regulating the assimilation, storage, and metabolism of nutrients. 
Disruption of these endocrine cells disturbs the normal control of body weight and 
insulin production and contributes to the development of type 2 diabetes (T2D). Two of 
these hormones, glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic 
polypeptide (GIP), are known as incretin hormones due to their ability to increase the 
β-cell insulin response to ingested glucose.1,2 It has been estimated that the incretin 
effect accounts for as much as 70% of insulin secretion in healthy persons and half of 
that in patients with T2D.3 Importantly, the incretin effect, in particular, postprandial 
production of GLP-1, is significantly impaired in patients with T2D.5
GLP-1 has been considered to be more important than GIP. GLP-1 is derived 
from the proglucagon gene expressed in pancreatic islet cells, L-cells of the small 
and large intestine, and neurons in the brainstem. Both transcription and translation 
are under the control of multiple tissue-specific regulatory mechanisms.6 The actions Therapeutics and Clinical Risk Management 2010:6 submit your manuscript | www.dovepress.com
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of GLP-1 are mediated through G-protein-coupled receptors 
widely expressed in pancreatic islet β cells throughout the 
gastrointestinal tract, kidney, lung, heart, major blood vessels, 
adipose tissue, on gastric vagal afferents, and in many brain 
regions.7–10 GLP-1 suppresses food intake through a pathway 
involving vagal afferent fibers, signaling to regions of the 
brainstem and hypothalamus. Thus, sustained administration 
of GLP-1 leads to weight loss in animals. Although the insu-
lin response to GIP is impaired in T2D, the response to GLP-1 
is preserved,11 making GLP-1 a feasible treatment. Further-
more, the administration of intravenous GLP-1 suppresses 
hyperglucagonemia in healthy subjects12 and normalizes 
blood glucose levels in patients with T2D.13 Gastric emptying 
is also delayed by GLP-1, and the increase in postprandial 
glucose is attenuated.14 Satiety is also increased,15 and the 
overall energy intake is reduced by treatment with GLP-1.16 
Thus, GLP-1 has many useful effects that make it appealing 
as a potential treatment of T2D.
The principal problem with GLP-1 as a therapeutic agent 
is that the N-terminal is rapidly cleaved by the enzyme dipep-
tidyl peptidase-IV (DPP-IV) resulting in the generation of 
inactive GLP-1-(9-36) amide.17,18 As a result, the half-life 
of GLP-1 after secretion is around 1.5 minutes,19 which is 
insufficient for a convenient frequency of injections to restore 
serum GLP-1 levels in humans. Therefore, a series of long-
acting receptor agonists of GLP-1 have been developed, and 
this class of drug is now making a major impact in the treat-
ment of T2D. This article compares the clinical pharmacology 
and therapeutics of the 2 currently available GLP-1 receptor 
agonists, exenatide and liraglutide, and comments on the 
choice between these drugs in clinical practice.
Clinical pharmacology
exenatide
Exenatide is a synthetic version of exendin-4, a molecule 
that is found in the saliva of the Gila monster. Exendin-4 has 
been found to have GLP-mimetic actions as an insulinotropic 
agent.20 Exenatide is a larger peptide than GLP-1, at 39 
rather than 20 amino acids, and shares 53% homology. 
Owing to a substitution of glycine for alanine at position 8, 
exenatide is resistant to degradation by DPP-IV . Exenatide 
binds more avidly to the GLP-1 receptor in humans than 
does GLP-1.21 These pharmacological differences make 
exenatide have a much longer half-life compared with 
GLP-1 (3.4–4 hours vs 1.5 minutes). Exenatide is detectable 
within the plasma 15 minutes after subcutaneous injection 
and remains detectable for up to 15 hours. As a peptide, 
exenatide is degraded rapidly in the stomach and, therefore, 
requires parenteral administration. Unlike GLP-1, exenatide 
undergoes renal excretion, and as a result, it has not been 
licensed for use in patients with estimated glomerular flow 
rate of ,30 mL/min.22,23 The administration of exenatide up 
to 1 hour before meals results in lower glucose levels post-
prandially than administration after a meal.24 These factors 
determine the recommended dosing regimen of exenatide, 
which is twice daily, up to 1 hour before meals, at least 
6 hours apart.
Liraglutide
Liraglutide is 97% homologous with human GLP-1, but 
  differs from native human GLP-1 by possessing an Arg34-
to-Lys34 substitution and a C16 fatty acid moiety bridged 
by glutamate at Lys.26 These changes confer resistance 
to enzymatic cleavage while the fatty acid moiety binds 
noncovalently to albumin, thereby lowering the absorption 
from the injection site and also reducing renal clearance. 
Thus, liraglutide reaches peak plasma concentrations after 
10–14 hours and has a half-life of 11–13 hours, making it 
suitable for once-daily administration irrespective of meal 
times.20 A property of GLP-1 receptor agonists that makes 
them attractive as therapeutic agents in diabetes is that insu-
lin secretion ceases when euglycemia is achieved, thereby 
minimizing the risk of hypoglycemia. Renal impairment has 
been found to have little effect on the pharmacokinetics of 
liraglutide, suggesting that the drug is likely to be safe to use 
in patients with kidney disease.25
Treatment of diabetes
exenatide
Initial trials found that 1 month of treatment with exenatide 
by subcutaneous injection twice daily significantly reduced 
plasma glucose levels and consequently hemoglobin A1c 
(HbA1c) in patients with T2D.26 The beneficial effects of 
exenatide on glycemic control were confirmed by a 4-week, 
blinded, placebo-controlled trial, in which exenatide reduced 
HbA1c by 0.8%–1.1% from baseline. Insulin secretion, as 
determined from the homeostasis model assessment, showed 
an increase of 50%–100% in those treated with exenatide 
at 14 and 28 days compared with baseline.27 Early trials 
did not demonstrate significant changes in weight and only 
encountered mild gastrointestinal side effects.
A series of good-quality, randomized, double-blinded, 
placebo-controlled phase III clinical trials have assessed the 
efficacy and tolerability of exenatide.28–30 The trials include 
combinations of exenatide or placebo with sulfonylurea, 
metformin, and metformin plus sulfonylurea. These studies Therapeutics and Clinical Risk Management 2010:6 submit your manuscript | www.dovepress.com
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are well designed but tend to suffer from relatively high 
  drop-out rates. The primary end points were HbA1c and safety, 
and the secondary end points were fasting plasma glucose 
level, weight, and adverse events.
A 30-week trial of exenatide at doses of 5 and 10 µg 
daily vs placebo added to existing sulfonylurea therapy in 
patients with type 2 diabetes mellitus found a reduction in 
HbA1c of 0.46% and 0.86%, respectively, compared with 
a 0.12% increase in HbA1c in the placebo group.28 Fasting 
plasma glucose was only significantly reduced in the 10 µg 
exenatide group. Similar effects on HbA1c were observed 
when exenatide was added to metformin monotherapy.29 
After 30 weeks of treatment with metformin and exenatide 
at the 5 or 10 µg doses, HbA1c decreased by 0.4% and 0.78%, 
respectively, compared with a small increase of 0.08% in 
HbA1c in the placebo group. Again, effects on fasting plasma 
glucose level were modest, reflecting the glucose-dependent 
insulinotropic effect of exenatide, reducing postprandial 
glucose more effectively than fasting glucose. In combination 
with metformin and sulfonylurea, exenatide 5 µg reduced 
HbA1c by 0.6% and 10 µg reduced HbA1c by 0.8% after 
30 weeks.30
More recent studies of a design comparable to the afore-
mentioned ones investigated the addition of exenatide or 
placebo to a combination of thiazolidinedione (pioglitazone 
or rosiglitazone) with or without metformin.31 In a 16-week 
study, HbA1c was reduced by 0.98% compared with placebo. 
In a 24-week study, exenatide 5 and 10 µg twice daily or pla-
cebo was given to drug-naive patients with T2D suboptimally 
controlled by diet and exercise. Both the 5 and 10 µg doses of 
exenatide improved HbA1c by 0.7% and 0.9%, respectively, 
in addition to improvements in fasting and postprandial 
plasma glucose levels. A recent open-label study random-
ized patients to exenatide, rosiglitazone, or the combination 
of both and found the greatest reduction in HbA1c of −1.3% 
in the combination therapy group. The combination also 
produced improvements in both insulin sensitivity and first- 
and second-phase insulin secretion.32
The comparative efficacies of exenatide and insulin have 
been investigated in 2 open-label trials. In a 26-week study, 
patients with suboptimally controlled T2D on metformin and 
sulfonylurea were assigned to receive 10 µg exenatide or once-
daily insulin glargine titrated to fasting blood glucose of ,5.6 
mmol/L.33 In both groups, HbA1c was reduced by 1.1%. In a 
16-week duration crossover study of exenatide 10 µg admin-
istered twice-daily vs once-daily insulin glargine, equivalent 
reductions of 1.36% were observed in HbA1c.34 Similar effects 
were found when exenatide 10 µg twice daily was compared 
with biphasic insulin aspart, in which HbA1c levels were 
reduced by 1.04% vs 0.89%, respectively.35 In these compari-
sons of insulin and exenatide, exenatide reduced postprandial 
glucose more effectively, whereas insulin produced greater 
reductions in fasting plasma glucose. Bunck et al36 randomized 
69 patients with T2D, already treated with metformin, to 
12-months treatment with exenatide or once-daily insulin 
glargine. The dose of exenatide varied from 5 µg twice daily 
to 15 µg thrice daily. The reductions in HbA1c were in line 
with those in other studies (0.8% and 0.7%, respectively), 
as were reductions in fasting plasma glucose (1.6 and 
2.9 mmol/L, respectively). At the end of the study period, 
both exenatide and insulin glargine were discontinued. Four 
weeks later, HbA1c and fasting plasma glucose had returned to 
pretreatment levels, indicating that continuous treatment with 
exenatide is required to maintain its efficacy. Data from an 
open-label extension to 3 double-blinded, placebo-controlled 
trials including 217 patients, with a mean body mass index 
(BMI) of 34 kg/m2, receiving treatment with exenatide over a 
period of 3 years have also been reported. A mean reduction 
of 1.0% in HbA1c was preserved for up to 3 years.37 Finally, 
in a study of 235 overweight patients inadequately controlled 
on   2 or 3 oral hypoglycemic agents and randomized to add-on 
exenatide or insulin glargine, similar mean HbA1c reductions 
of −1.25 and −1.26%, respectively, were observed. However, 
53.4% of exenatide-treated patients reached the composite end 
point of HbA1c ,7% and weight gain ,1 kg, compared with 
just 19.8% of the insulin glargine-treated group.38
The rates of hypoglycemia observed with exenatide 
treatment are largely dependent on the drugs with which it 
is combined. When exenatide was used alone, there were low 
rates of mild hypoglycemia (4%–5% and not significantly 
different from placebo), and no severe hypoglycemic events 
were reported.39 When exenatide was used in combination 
with metformin or in combination with both metformin 
and thiazolidinedione, there were also no increased risks 
of hypoglycemia.29,31 However, when it was combined with 
sulfonylurea (either alone or with metformin), there was 
an increase in the risk of mild to moderate hypoglycemia 
compared with placebo.28,30 There was only one incident of 
severe hypoglycemia in a patient treated with exenatide 5 µg 
and sulfonylurea that required assistance from a third person. 
The incidence of hypoglycemia was similar when once-daily 
insulin glargine was compared with twice-daily exenatide 
10 µg.33 Most incidences of hypoglycemia were mild or 
moderate, but there were 4 episodes of major hypoglycemia 
in each group. Hypoglycemia was more common in those 
patients achieving a lower target level of HbA1c ,7% (61% Therapeutics and Clinical Risk Management 2010:6 submit your manuscript | www.dovepress.com
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with exenatide and 68% with insulin glargine). Nocturnal 
hypoglycemia was also more common in the insulin glargine-
treated group, while daytime hypoglycemia was more 
common in the exenatide-treated group. Similar findings 
were reported in the study of Davies et al.38 Although the 
occurrence of hypoglycemia may reflect an overall reduction 
in glucose levels that predisposes patients to a greater 
risk of hypoglycemia from concomitant administration 
of sulfonylureas, in vitro studies have shown that GLP-1 
augments the insulin-releasing action of sulfonylureas.40 
Therefore, the combination of a GLP-1 receptor agonist 
and sulfonylurea may be intrinsically more likely to result 
in hypoglycemia because of the closely related mechanism 
of action of these 2 classes of drugs.
Antibodies to exenatide were detected in approximately 
40%–50% of patients receiving exenatide in phase III 
trials.28–30 The presence of antibodies appears to have no 
correlation with drug action, glycemic control, or adverse 
effects. Although the most common adverse effects 
are gastrointestinal (nausea, vomiting, and abdominal 
discomfort), exenatide is generally well tolerated. The 
gastrointestinal side effects were generally mild to moderate 
and tended to decrease with duration of treatment. Slow 
titration of exenatide also has been shown to reduce the rate 
of gastrointestinal side effects.41 The percentage of with-
drawals attributed to nausea was low. The principal clinical 
trials of exenatide in patients with T2D are summarized in 
Table 1.
Exenatide has also been studied in combination with 
insulin, although this use currently remains off license. In 
an observational study of 134 patients treated with exenatide 
and insulin for at least 12 months, the addition of exenatide 
was associated with 45% discontinuation of soluble insulin, 
an average 9 units of reduction in soluble insulin doses, 
reduction in numbers of insulin injections from 2 to 1, and 
59% discontinuation of sulfonylurea treatment. Despite these 
treatment reductions, there was a mean reduction of 0.87% 
in HbA1c.42 In another retrospective observational study of 
268 patients treated with both exenatide and insulin for up 
to 27 months, mean reductions in HbA1c were around −55%, 
with reductions in soluble insulin doses of up to 55%.43
Liraglutide
Early randomized controlled studies using liraglutide at low 
doses in patients with T2D found that this drug was well toler-
ated, at least as effective as metformin, and was not associated 
with weight gain.44,45 The efficacy of the drug was confirmed 
in a randomized, placebo-controlled, dose-ranging study of 
5 weeks duration. Liraglutide alone reduced HbA1c by 0.8%, 
fasting plasma glucose by 3.9 mmol/L, and body weight by 
2.2 kg compared with the combination of liraglutide and 
metformin. In addition, the combination therapy of liraglutide 
and metformin vs metformin and glimepiride significantly 
reduced the fasting glucose by 1.2 mmol/L.46 In another study 
of 14 weeks duration, liraglutide exhibited a dose-dependent 
decrease of HbA1c and increased the proportion of patients 
achieving good glycemic control.47
The role of liraglutide in the treatment of diabetes has 
been further defined in a programme of large scale, longer-
duration clinical studies initiated by the manufacturers. This 
programme, known as the “Liraglutide Effect and Action 
in Diabetes” (LEAD) programme, has compared liraglutide 
with existing oral hypoglycemic therapies, as a single 
agent and in combinations. These trials are summarized in 
Table 2. LEAD 3 compared liraglutide with sulfonylurea 
glimepiride. In LEAD 1, 2, and 4 studies, liraglutide was 
added to other oral hypoglycemic agents. In LEAD 5, 
liraglutide and insulin glargine were compared as add-on 
therapy with metformin and glimepiride. Finally, LEAD 6 
compared the addition of liraglutide or exenatide to treat-
ment with metformin and/or glimepiride. These trials were 
all well-designed, controlled studies with a priori power 
calculations. Generally, follow-up and ascertainment of 
outcomes were well conducted, and apart from the LEAD 3 
study,48 drop-out rates were low.
In the LEAD study programme, reductions in HbA1c 
with addition of liraglutide ranged between 0.8%–1.5% at 
1.2 and 1.8 mg doses, and liraglutide appeared somewhat 
more effective in patients who had previously received 
monotherapy rather than combination therapy.49,50 The 
proportion of patients achieving glycemic targets with 
liraglutide was also consistently higher than that in the 
comparison groups. Notably, the LEAD 6 is the only study so 
far to compare liraglutide and exenatide. This 26-week trial 
randomized 233 patients to liraglutide 1.8 mg daily and 231 to 
exenatide 10 µg twice daily. The mean BMI of these patients 
was approximately 33 kg/m2 and mean HbA1c at baseline 
was 8.2%. The patients were already treated with metformin, 
sulfonylurea, or both. Liraglutide lowered mean HbA1c by 
1.12% compared with 0.79% with exenatide, which gave a 
significant treatment difference. About 54% of liraglutide-
treated patients achieved HbA1c , 7% compared with 43% 
of exenatide-treated group. Fasting blood glucose level 
was lower with liraglutide, but postprandial blood glucose 
level was higher.51 Overall, this study suggested a small but 
  significant benefit of liraglutide over exenatide.Therapeutics and Clinical Risk Management 2010:6 submit your manuscript | www.dovepress.com
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In LEAD 3 and LEAD 2, the rates of minor hypoglycemia 
were significantly lower in liraglutide-treated group than 
in glimepiride-treated groups, and no major hypoglycemic 
events were recorded in these studies.48,49 In LEAD 1, in 
which the baseline treatment was with sulfonylurea, minor 
hypoglycemia was more frequent with liraglutide add-on 
treatment compared with rosiglitazone add-on treatment.50 
In LEAD 4, the rate of minor hypoglycemia was also higher 
with liraglutide than with placebo, although no serious 
hypoglycemia was observed.52 In LEAD 5, the frequency of 
minor hypoglycemia was similar with both insulin glargine 
and liraglutide, although 5 patients treated with liraglutide 
reported major hypoglycemic events.53 Finally, in LEAD 6, 
liraglutide was associated with fewer minor hypoglycemic 
events than exenatide, and 2 patients receiving treatment 
with exenatide and sulfonylurea experienced major hypo-
glycemia.51 In patients receiving liraglutide in addition to 
metformin or rosiglitazone, the risk of hypoglycemia was 
very low. Thus, the risk of hypoglycemia with GLP receptor 
antagonists appears higher in specific combination therapy 
with sulfonylureas.
The most frequent adverse effects are gastrointestinal 
intolerance, especially nausea. However, this subsides soon in 
most patients. In LEAD 6, liraglutide and exenatide produced 
similar initial rates of nausea, although by the end of the 
study, there was a significantly greater rate of nausea in the 
exenatide-treated group. Although adverse event rates were 
low, the liraglutide group reported slightly more serious and 
severe adverse events than the exenatide group.51 Six cases of 
pancreatitis were also reported during the LEAD programme, 
and all but 5 were in liraglutide-treated patients. In LEAD 
6, although there was 1 episode of mild pancreatitis in the 
liraglutide-treated group, liraglutide treatment was continued 
in that patient.51 However, a recent commentary on this sub-
ject draws attention to 7 reported cases of pancreatitis out of 
4,257 patients treated in phase II and III trials of liraglutide 
compared with just 1 case of pancreatitis in the 2,381 patients 
who received comparator treatments. After adjustment for 
patient-years of exposure to liraglutide, this study represented 
a 4-to-1 imbalance between the liraglutide and comparator 
groups.54 Therefore, although there may be a small risk of 
pancreatitis, the number of patients affected is small, and so 
the magnitude of this risk is difficult to determine.
The long-term treatment of rodents with liraglutide was 
found to cause thyroid C-cell hyperplasia, which raised the 
concerns that long-acting GLP-1 agonists might carry an 
increased risk of medullary thyroid cancer. Although the 
primate C-cells are apparently much less sensitive to GLP-1 
  receptor agonists,55 and this highlights the need for long-term 
  postmarketing surveillance of new classes of drugs.
Effects on body weight
exenatide
Exenatide has consistently caused significant weight loss 
in a range of clinical trials. These effects are summarized 
in Table 1. As a GLP-1 receptor agonist, exenatide also 
has a variety of nonglycemic effects on appetite and gastric 
emptying. Three placebo-controlled trials have demonstrated 
significant dose-dependent weight loss with exenatide 
compared with placebo. When exenatide was added to sul-
fonylurea therapy alone, there was a weight loss of 1.6 kg 
in the 10-µg dose group compared with 0.6 kg weight loss 
in the placebo group.28 When exenatide at doses of 10 and 
5 µg was added to metformin and sulfonylurea, it elicited the 
weight loss of 1.6 kg in both groups compared with 0.9 kg 
in the placebo group.30 Exenatide added to metformin alone 
caused the greatest weight reduction of 1.6 and 2.8 kg at the 
5 and 10 µg doses, respectively.29 Similar weight reduction 
was observed with exenatide at 10-µg dose in patients treated 
with a combination of rosiglitazone or pioglitazone with or 
without metformin, with an average weight loss of 1.74 kg 
over 32 weeks.31 In another randomized study, exenatide 
10 µg twice daily combined with rosiglitazone 4 mg elicited 
average weight loss of 1.2 kg in contrast to the weight gain 
of 1.5 kg with rosiglitazone alone and weight loss of 2.8 kg 
with exenatide alone.32
In the open-label extension of the 3 phase III clinical 
trials of exenatide, there was a progressive weight loss in 
those treated with exenatide 10 µg for 3 years. Although 
this was an uncontrolled trial, in 217 subjects, the mean 
weight loss was 5.3 kg at 3 years.37 In a 30-week study, mean 
weight loss was 3.0 kg, whereas this also reached 5.3 kg 
after 82 weeks.56 Therefore, weight loss with exenatide 
may reach a plateau after about 18 months. In these studies, 
weight loss with exenatide was apparently independent of 
gastrointestinal side effects.
Exenatide as monotherapy in drug-naive patients with 
T2D has also shown significant weight loss. After 24 weeks 
of treatment with exenatide 5 µg, 10 µg, or placebo, mean 
weight loss was 2.8, 3.1, or 1.4 kg, respectively.39 In open-
label comparisons of exenatide, insulin glargine, and biphasic 
insulin aspart, the value of exenatide as an adjunctive therapy 
was highlighted.33,35,38 Although these 3 therapies improved 
glycemic control to comparable extents, exenatide was asso-
ciated with significant weight loss, whereas insulin leads to 
weight gain. When insulin glargine was added to metformin Therapeutics and Clinical Risk Management 2010:6 submit your manuscript | www.dovepress.com
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and sulfonylurea, the weight gain was 1.8 kg compared with 
weight loss of 2.3 kg in the exenatide-treated patients.33 
After 1 year of treatment with biphasic insulin aspart, the 
weight gain was 2.9 kg compared with weight loss of 2.5 kg 
with exenatide.35 In another study, add-on treatment with 
exenatide resulted in 2.73 kg of weight loss compared with 
2.98 kg weight gain in the glargine-treated group, an overall 
difference of 5.71 kg.38 Interestingly, exenatide also evoked 
average weight losses of 5.2 kg42 and 5.5 kg43 when used 
in combination with insulin. Finally, in a small open-label 
trial in women with polycystic ovary syndrome, the effect 
of treatment with metformin alone, exenatide alone, or the 
combination of both on the menstrual regularity and weight 
was evaluated. Metformin alone led to the weight loss of 
1.6 kg, exenatide alone to 3.2 kg, and the combination of both 
to 6 kg.57 Otherwise, there are only limited published data on 
the use of exenatide in patients with nondiabetic obesity.
Liraglutide
The beneficial effect of liraglutide on body weight was 
observed in all the early studies of this drug,44–47 and sig-
nificant dose-dependent weight loss was demonstrated in all 
of the LEAD studies. In the monotherapy study (LEAD 3), 
absolute weight loss was 2.5 kg at the 1.8 mg dose and 2.1 kg 
at the 1.2 mg dose. Weight loss was greatest in combination 
with metformin: 2.8 kg with the 1.8 mg dose and 2.6 kg with 
the 1.2 mg dose.49 In LEAD 1, the addition of liraglutide to 
sulfonylurea abolished the weight gain observed in the group 
treated with the combination of sulfonylurea and rosiglita-
zone.50 In combination with metformin and rosiglitazone, 
weight loss was 2 kg at the 1.8 mg dose and 1 kg at the 1.2 mg 
dose.52 In LEAD 5, treatment with insulin glargine increased 
weight by 1.6 kg, whereas liraglutide decreased weight by 
1.8 kg.53 In LEAD 6, at the 1.8 mg dose, liraglutide elicited 
weight loss of 3.2 kg compared with 2.9 kg in the exenatide 
group.51 The reduction of body weight with liraglutide is 
confirmed to result from a reduction in body fat.58 Therefore, 
liraglutide-induced weight loss is maximal in metformin-
treated patients, but liraglutide appears to offset the weight 
gain that often results from treatment with sulfonylurea, 
thiazolidinediones, or insulin. These effects on body weight 
are summarized in Table 2.
A potential role of liraglutide as a weight loss treatment 
is emerging. In a recently reported trial of 20 weeks duration, 
564 obese individuals with BMI 30–40 kg/m2 were randomly 
assigned to any one of 4 doses of liraglutide (1.2, 1.8, 2.4, 
or 3.0 mg), placebo, or orlistat. All subjects were advised 
for a 500-calorie energy-deficit diet and to increase physical 
activity. Subjects on liraglutide lost significantly more weight 
than did those on placebo and orlistat. Mean weight loss with 
these 4 doses of liraglutide was 4.8, 5.5, 6.3, and 7.2 kg vs 
2.8 kg in the placebo group and 4.1 kg in the orlistat group. 
About 76% of individuals lost more than 5% weight with 
liraglutide 3.0 mg compared with 30% in the placebo or 44% 
in the orlistat groups. Liraglutide reduced blood pressure at 
all doses and improved glucose tolerance. Although transient 
nausea was the commonest adverse effect, liraglutide was 
generally well tolerated at these higher doses.59 Therefore, 
liraglutide is a promising drug for weight loss. All these 
observations are more important in view of the withdrawal 
of rimonabant and sibutramine, which has severely restricted 
the current choice of drugs for weight loss.
Effects on blood pressure
An unexpected but consistent effect of liraglutide in the 
LEAD programme was the modest reduction of blood 
pressure, ranging from 2.1 to 6.7 mm Hg.49,51–53,60 GLP-1 
has been reported to have a natriuretic effect,61 which 
might explain its effect on blood pressure. In contrast, a 
recently reported randomized, controlled trial in patients 
treated with metformin and/or thiazolidinedione compared 
the effect of exenatide or placebo on ambulatory blood 
pressure. However, although a nonsignificant trend was 
suggested,62 no reduction of blood pressure was observed 
with exenatide. However, in a pooled analysis of data from 
6 trials involving 2,171 patients, systolic blood pressure was 
reduced in the exenatide-treated groups by 2.8 mm Hg when 
compared with placebo and by 3.7 mm Hg when compared 
with insulin-treated patients, but no effect was observed on 
diastolic blood pressure. The reduction in blood pressure 
appeared highest in patients with systolic blood pressure of 
.150 mm Hg. A weak correlation between weight loss and 
blood pressure reduction was also observed.63 Vasorelaxant 
effects of GLP-1 have been observed in various animal and 
in vitro studies,64–66 and infusion of GLP-1 in humans with 
T2D leads to increased flow-mediated vasodilatation in the 
brachial artery.67 Therefore, GLP-1 and GLP-1 receptor 
agonists appear to possess the useful additional property of 
reducing blood pressure. Furthermore, one may speculate 
that reduced GLP-1 secretion could be a factor contributing 
to the increased prevalence of hypertension among patients 
with T2D.
Conclusions
GLP-1 receptor agonists are one of the most significant recent 
advances in the treatment of T2D. Although weight loss is Therapeutics and Clinical Risk Management 2010:6 submit your manuscript | www.dovepress.com
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regularly identified as a treatment priority for patients with 
T2D, it is ironic that many patients find that the established 
pharmacological approaches to treatment with sulfonylureas, 
thiazolidinediones, and insulin only improve glycemic con-
trol at the cost of significant weight gain. GLP-1 receptor 
agonists have rapidly established a place as add-on therapy 
to other oral agents, in preference to a direct move onto 
insulin treatment. Clearly, long-term studies will be required 
to compare these strategies. GLP-1 receptor agonists also 
seem to have a significant potential as weight loss drugs in 
persons both with and without T2D; however, in view of the 
historical problems with weight loss drugs, it is important to 
demonstrate their long-term safety and efficacy in this role. 
Because prevention of cardiovascular disease is an important 
objective in treating patients with T2D, it is now essential 
to demonstrate the apparently favorable short-term effects 
of GLP-1 receptor agonists on glycemic control and weight 
observed in clinical trials to date translate into safe and effec-
tive long-term reductions of diabetes-related cardiovascular 
events and other relevant clinical end points.
Liraglutide and exenatide differ in several respects, and 
these differences are likely to influence clinical choices. 
The once-daily dosage of liraglutide makes this drug more 
appealing than exenatide for a group of patients who are often 
already receiving many different medicines. The convenience 
of being able to take liraglutide at any time of the day, irre-
spective of meal times, is also attractive. The LEAD 6 study 
suggests that liraglutide is somewhat more effective than 
exenatide in lowering the blood glucose and HbA1c levels. 
Both drugs are relatively well tolerated, and serious hypogly-
cemia is very unusual; nevertheless, liraglutide may be less 
liable to cause hypoglycemia. Liraglutide also consistently 
reduces blood pressures, whereas this effect may be less 
marked or absent with exenatide. Compared with exenatide, 
the absence of allergy to liraglutide, which is largely homolo-
gous with human GLP-1, also favors liraglutide. Pharmacoki-
netic considerations suggest that there may be less risk of 
drug accumulation with liraglutide compared with exenatide, 
so that liraglutide might be tolerated better by patients with 
diabetic nephropathy. However, we were unable to identify 
any additional reports on patients with advanced nephropathy. 
Although both liraglutide and exenatide induce gastrointesti-
nal side effects, this effect is of significantly shorter duration 
with liraglutide, enabling more patients to continue the drug. 
Finally, while both drugs clearly elicit weight loss, which is 
highly desirable for all patients with T2D, the observation 
that liraglutide is significantly more effective than orlistat in 
a randomized, controlled trial may also make this drug an 
important treatment choice for many patients. Thus, GLP-1 
receptor agonists are becoming favorable alternative to the 
existing hypoglycemic therapies that are of modest efficacy 
and usually result in weight gain.
Currently, several considerations appear to favor the 
selection of liraglutide over exenatide. However, the develop-
ment of new long-acting formulations such as once-weekly 
exenatide, which was more effective in lowering HbA1c than 
exenatide administered twice daily,68 clearly has the potential 
to influence this choice. Several new GLP-1 receptor ago-
nists, including agents that may be taken orally, are also in 
development, and it remains to be seen how such drugs will 
compare with the existing 2 agents.
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